Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2002-12-05
2008-09-02
Helms, Larry (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S069600, C435S320100, C536S023530, C536S024100
Reexamination Certificate
active
07419659
ABSTRACT:
The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linked by an optimised intergenic sequence.
REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 5698435 (1997-12-01), Robinson et al.
patent: 7018809 (2006-03-01), Carter
patent: 2005/0042219 (2005-02-01), Woulfe et al.
patent: 2005/0181448 (2005-08-01), Popplewell et al.
patent: 0 120 694 (1984-10-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0124317.9 (2001-10-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 95/01155 (1995-01-01), None
patent: WO 01/94585 (2001-06-01), None
patent: 01/94585 (2001-12-01), None
Muller et al. (FEBS Letters 422:259-264 (1998).
Cheung et al. (J. Virology 66(11):6714-6720 (1992).
Sequence search alignment for SEQ ID Nos. 4, 7, 10 and 13 (pp. 1-4).
Adhin, M.R. and van Duin, J., “Scanning Model for Translational Reinitiation in Eubacteria,”J. Mol. Biol., 213:811-818, (1990).
Andre, A., et al., “Reinitiation of protein synthesis inEscherichia colican be induced by mRNAcis-elements unrelated to canonical translation initiation signals,”FEBS Letters, 468:73-78, (2000).
Begent, R. H. J., et al., “A Serum Factor With Potential As A Tumour Marker In Malignant Lymphoma,”Br. J. Cancer, 41:481-484, (1980).
Better, M., et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,”Science, 240:1041-1043, (May 20, 1988).
Knappik, A. and Plückthun, A., “Engineered turns of a recombinant antibody improve its in vivo folding,”Protein Engineering, 8(1):81-89, (1995).
Köhler, G. and Milstein, C., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 256:495-497, (Aug. 7, 1975).
Koppel, G.A., “Recent Advances with Monoclonal Antibody Drug Targeting for the Treatment of Human Cancer,”Bioconjugate Chem., 1:13-23, (1990).
Makrides, S.C., “Strategies for Achieving High-Level Expression of Genes inEscherichia coli,” Microbiological Reviews, 60(3):512-538, (Sep. 1996).
Oeltmann, T.N. and Frankel, A.E., “Advances in immunotoxins,”FASEB J., 5:2334-2338, (1991).
Riechmann, L., et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, (Mar. 24, 1988).
Simmons, L.C. and Yansura, D.G., “Translational level is a critical factor for the secretion of heterologous proteins,”Nature Biotechnology, 14:629-634, (May 1996).
Spanjaard, R.A. and van Duin, J., “Translational reinitiation in the presence and absence of a Shine and Dalgarno sequence,”Nucleic Acids Research, 17(14):5501-5507, (1989).
van den Bergh, H., “Light and porphyrins in cancer therapy,”Chemistry in Britain, pp. 430-439, (May 1986).
Vaughan, T.J., et al., “Human antibodies by design,”Nature Biotechnology, 16:535-539, (1998).
Waldman, T.A., “Monoclonal Antibodies in Diagnosis and Therapy,”Science, 252:1657-1662, (Jun. 21, 1991).
Published PCT International Search Report dated Jun. 12, 2003 for International Application No. PCT/GB2002/005466, International Filing Date: Dec. 5, 2002.
Bristol Lynn
Cozen O'Connor
Helms Larry
UCB Pharma S.A.
LandOfFree
Expression control using variable intergenic sequences does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression control using variable intergenic sequences, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression control using variable intergenic sequences will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981163